Status: Recruiting
TRUDI: TDXD+Durva in HER2+/Low IBC
The purpose of this study is to test the safety and effectiveness of an investigational drug combination (trastuzumab deruxtecan and durvalumab) to learn whether the intervention works in treating Human Epidermal growth factor Receptor-2 (HER2)-expressing inflammatory breast cancer. The names of the study drugs involved in this study are: * Trastuzumab deruxtecan * Durvalumab
Participants needed: 63
Trial details
Phase: Phase 2Age: 18+Biological sex: FemaleType: InterventionalSponsor: Filipa Lynce, MDUpdated: Sep 19, 2025Locations: 3
Eligibility criteria
Participants must have a histological or cytological diagnosis of invasive breas... [+23]
Has received prior systemic anti-cancer therapy for the current diagnosis of inf... [+22]